Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Corporate Presentation

Latest News

Imunon Appoints James E. Dentzer to its Board of Directors

October 3, 2022

Imunon Reports Partial Results from Ongoing Non-human Primate Study

October 3, 2022

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

September 29, 2022

Financial Events

Imunon Corporation Presentation_Chardan’s 6th Annual Genetic Medicines Conference

October 3, 2022 at 2:30 PM EDT

Celsion Corporation Presentation_September 2022_HC Wainwright Investment Conference

September 13, 2022 at 4:30 PM EDT